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A Randomized Trial of Anticoagulants 
Versus Aspirin after Cerebral Ischemia of 
Presumed Arterial Origin
The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group *
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Aspirin is only modestly effective in the secondary prevention after cerebral ischemia. Studies in other vascular disorders 
suggest that anticoagulant drugs in patients with cerebral ischemia of presumed arterial (noncardiac) origin might be 
more effective. The aim of the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) therefore was to compare the 
efficacy and safety of 30 mg aspirin daily and oral anticoagularion (international normalized ratio [INR] 3.0—4.5). 
Patients referred to a neurologist in one of 58 collaborating centers because of a transient ischemic attack or minor 
ischemic stroke (Rankin grade ^3) were eligible. Randomization was concealed, treatment assignment was open, and 
assessment of outcome events was masked. The primary measure of outcome was the composite event “death from all 
vascular causes, nonfatal stroke, nonfatal myocardial infarction, or nonfatal major bleeding complication.” The trial was 
stopped at the first interim analysis. A total of 1,316 patients participated; their mean follow-up was 14 months. There 
was an excess of the primary outcome event in the anticoagulated group (81 of 651) versus 36 of 665 in the aspirin 
group (hazard ratio, 2.3; 95% confidence interval [Cl], 1.6—3.5). This excess could be attributed to 53 major bleeding 
complications (27 intracranial; 17 fatal) during anticoagulant therapy versus 6 on aspirin (3 intracranial; 1 fatal). The 
bleeding incidence increased by a factor of 1.43 (95% Cl, 0.96-2.13) for each 0.5 unit increase of the achieved INR.
Anticoagulant therapy with an INR range of 3.0 to 4.5 in patients after cerebral ischemia of presumed arterial origin is 
not safe. The efficacy of a lower intensity anticoagulation regimen remains to be determined.
The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants 
versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865
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Patients who have had a transient ischemic attack (TIA) 
or nondisabling ischemic stroke have an annual risk of
important vascular events from all vascular causes,
nonfatal stroke, or nonfatal myocardial infarction) rang­
ing between 4% and 16% in clinical trials [1, 2]. The 
corresponding estimate for population-based studies is
9% per year [3]. Aspirin, in any daily dose from 30 mg 
on, offers only modest protection after cerebral ischemia; 
it reduces the incidence of major vascular events by 20%
at most 1, 2
c
. Oral anticoagulant drugs might be 
more effective in preventing vascular complications after 
cerebral ischemia. Secondary prevention trials after myo- 
ardial infarction indicate that treatment with oral anti­
coagulant drugs is associated with a risk reduction ap­
proximately twice that of treatment with aspirin or other 
antiplatclet drugs [1, 5-8]. Both treatment with aspirin 
and anticoagulants increases the risk of bleeding compil­
ations [2, 9]. Few data are available on the efficacy and
The Stroke Prevention In Reversible Ischemia Trial 
T) was an :r, con­
ti- -dose anticoagulation
, 3.0-4.5) versus(international norm;
low-close aspirin (30 mg/day) in patients with a TIA or
stroke of arterial
(noncardiac) origin. The current target range of anti­
coagulation for the prevention of arterial disease in The
as by the Federation of 
Dutch Thrombosis Centers, was an INR range of 3.0
to 4.5 [121. i a r n used in the
secondary prevention trials after myocardial infarction;
2.7 to 4.5 in the Sixty Plus Study [5], 2.8 to 4.8 in 
(WARIS) ¡o 111 .icoatiuiants
in Prevention of Events in Cloro nary
Thrombosis (ASPECT) study [7|. In several o 
countries compar; ■'intensity are to pro-
r J
safety of oral anticoagulant treatment in patients with vent arterial complications 1131. Io  use the hill thera- 
cerebral ischemia [10], except in those with atrial Fibril- peutic potential of anticoagulation, we used the IN R
lation [11]. range of 3.0 to 4.5.
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Patients and Methods
Eligible Patients
Patients referred to a neurologist or general physician at one 
of the collaborating centers (see Appendix) were eligible for 
the trial if they had had a TIA or minor ischemic stroke 
(grade ^ 3  on. the modified Rankin scale [14, 15]) within the 
preceding 6 months. Patients were excluded it they had ce­
rebral ischemia due to high-grade carotid stenosis requiring 
surgery or by embolism secondary to atrial fibrillation, car­
diac valve disease, or a recent myocardial infarction. Patients 
with disorders of blood coagulation or those with a (contra) 
indication for oral anticoagulation or aspirin were also ex­
cluded. The study protocol was reviewed and approved by 
the institutional review boards of the participating hospitals. 
All patients were informed, about the background and pro­
cedures of the trial and gave their explicit consent.
Baseline Characteristics
At the time of randomization, data were collected on the 
nature of the longest episode of focal neurological deficits 
during the last 6 months as well as on duration, mode of 
onset, and number of attacks. Demographic data, the grade 
on the modified Rankin scale, vascular risk factors, and vas­
cular history were recorded. Computed tomography (CT) of 
the brain was required in all patients except those with tran­
sient monocular blindness. Chest radiography and electrocar­
diography (ECG) were mandatory; duplex scanning of the 
carotid arteries was optional.
Treatment
Patients eligible for the trial were randomly assigned to open 
treatment with either aspirin or oral anticoagulant treatment. 
Balance between treatment assignments within hospitals was 
achieved with the use of random permuted blocks. Random­
ization codes were centrally stored in a computer and com­
municated by telephone to the neurologists on enrollment of 
a new patient. A computer file containing all randomization 
codes was submitted to the Data Monitoring Committee at 
the start of the study. Aspirin was prescribed as pulverized 
carbasalate calcium (Ascal) in a dose of 38 mg (equivalent to 
30 mg aspirin) daily. If a participating center preferred this, 
regular aspirin could be prescribed in higher doses, up to 100 
mg daily. The patients were advised to take only acetamin­
ophen as an analgesic agent.
The preferred anticoagulant drug was phenprocoumon 
(Marcoumar) because more stable anticoagulation is expected 
with this drug than with short-acting preparations, but 
acenocoumarol (Sintrom mitis) and warfarin (Australian, 
Italian, and UK centers) were also used. In The Netherlands 
the dose of the anticoagulant drug was adjusted by local 
thrombosis centers and in the other countries by hospital- 
based physicians. At each visit the prothrombin time was 
measured and converted to an INR; the target value was 3.5 
and the target range was an INR value of 3.0 to 4.5.
the trial (see below), follow-up data of all patients were com­
pleted up to May 15, 1996, including auditing of all out­
come events not yet reported at the time of the first interim 
analysis. At each contact the occurrence of any potential out­
come event, hospital admissions, and possible adverse effects 
were recorded as well as current handicap (by means of the 
modified Rankin scale) and changes in trial medication. 
Follow-up was complete in all patients.
Follow- Up
Every 6 months all patients were seen by their neurologist, 
or, if this was not possible, follow-up information was ob­
tained from the general practitioner or by telephone contact 
with the patient or caregiver. After premature termination of
Outcome Events
The primary outcome measure was the composite event 
“death from all vascular causes, nonfatal stroke, nonfatal 
myocardial infarction, or nonfatal major bleeding complica­
tion,” whichever occurred first. Secondary outcome events 
were death from all causes, death from vascular causes, and 
death from vascular causes or nonfatal stroke. After the pre­
mature termination of the trial, we defined post hoc a ter­
tiary outcome event for explanatory purposes, ie, any major 
ischemic event, namely, nonhemorrhagic death from vascular 
causes, nonfatal ischemic stroke, or nonfatal myocardial in­
farction. Death from vascular disease included sudden death 
(reliable observation of the time between onset of symptoms 
and death, or the patient being found dead), or death from 
stroke, myocardial infarction, congestive heart failure, any 
bleed, peripheral vascular disease, pulmonary embolism, or 
other vascular causes. The diagnosis of nonfatal stroke re­
quired a focal neurological deficit of sudden onset persisting 
for more than 24 hours, with an increase in handicap of at 
least one grade on the Rankin scale. CT scanning was en­
couraged after each possible stroke; these scans were audited 
by physicians blinded to treatment allocation. Myocardial in­
farction was defined by at least two of the following: history 
of chest discomfort for at least half an hour, specific cardiac 
enzymes more than twice the upper limit of normal, or the 
development of new Q  waves on the standard 12-lead ECG. 
The definition of major bleeding complication included in­
tracranial bleeding, fatal bleeding, and any bleeding requiring 
hospitalization irrespective of interventions.
All events were independently classified by three members 
of the auditing committee for outcome events. The reviewers 
were blinded to the assigned treatment; in case of differences 
of opinion, the outcome event was discussed in the Executive 
Committee and decided by majority vote.
Calculation o f INR-Specific Event Rates
Intensity-specific incidence rates were calculated as the ratio 
of the number of events that took place at a certain achieved 
intensity of INR (subdivided according to intervals of 0.5 
INR units) and the number of patient-years that this INR 
level had been achieved by the patient population. This 
method has been described in detail by Rosendaal and col­
leagues [16]. The INR at the time of an outcome event was 
obtained from the hospital records. If this measurement had 
not been performed or could not be retrieved, we used the 
last INR measurement at the anticoagulation clinic within 8 
days before the event. If this information was not available, 
the event was disregarded for this purpose.
Size o f the Study and Interim Analysis
We calculated that 3,000 patients should be followed for a 
mean period of 2.9 years to detect a relative decrease of 24%
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in the incidence of the primary outcome event in the anti- 
coagulated group, assuming a type I error of 5%, a type II 
error of 20%, and an incidence of the primary outcome 
event of 6 per 100 patient-years in the aspirin group [4].
During the trial, none of the investigators had knowledge 
of event rates or complication rates according to treatment 
allocation. An independent Data Monitoring Committee (a 
neurologist, a hematologist, and an epidemiologist/statisti­
cian) monitored the study results. Five interim analyses were 
planned, each after an additional 1,500 patient-years had 
been accrued; an asymmetrical stopping rule was agreed on 
[17]. This asymmetry was chosen because we considered the 
amount of evidence needed to rule out a positive effect of 
anticoagulant therapy to be smaller than that to prove its 
superiority above aspirin. At the end of April 
blinded data on approximately 1,200 person-years for the 
first interim analysis were submitted to the Data Monitoring 
Committee. On the basis of that analysis (primary outcome 
event, as for as known by that time, had occurred in 54 of 
the 616 patients allocated to anticoagulant treatment and in 
26 of the 627 patients in the aspirin group; relative risk, 2.1; 
95% confidence interval [Cl], 1.3—3.3) the Data Monitoring 
Committee advised the Steering Committee on May 6 to 
stop the trial in its original design. Soon thereafter all par­
ticipating neurologists and thrombosis centers were informed 
that the trial was stopped for all patients; patients on anti­
coagulant treatment were switched to low-dose aspirin.
un-
Data Analysis
The principal aim of the data analysis was to compare the 
incidence of the primary outcome event between the antico­
agulation and aspirin treatment strategies. The analysis was
on the intention-to-treat principle; that is, whether 
medication was taken or not, the patients were analyzed ac­
cording to their originally assigned treatment. The occur­
rence of the primary outcome event in the two groups was
compared in terms of the hazard ratio (HR), which may be 
interpreted as a relative risk. HRs were obtained by means of 
the Cox proportional hazard model [18]. The precision of 
the HR estimates’ was described with the 95% CIs obtained 
from the Cox model. A Poisson model was fitted to deter-
patients, however, were included in the intention-to- 
treat analysis. Table 1 shows the characteristics of the 
patients at baseline. Approximately two-thirds of the 
patients were males and the mean age was 63.3 
(±10.5) years. The longest episode of cerebral ischemia
had occurred within the previous month in about half
the patients; approximately 40% had had a TIA. Base­
line CT scans of the brain were available in all but 46 
patients; in 25 patients with transient monocular 
blindness it was not required and in 21 patients with 
cerebral ischemia the scan was missing. All but three 
qualifying events with any relevant infarct on the base­
line CT scan were classified as ischemic; two ischemic 
lesions were rated as moderately hemorrhagic and one 
as severely hemorrhagic; no outcome event occurred in 
these 3 patients. Most CT scans were done within 2 
weeks after onset of symptoms of the qualifying event 
(65%), another 13%) was done between 2 and 4 weeks.
•e were no major •enees
with regard to prognostic variables at baseline.
Patients randomized to aspirin and anticoagulant 
drugs equally often visited their randomizing physician. 
Almost all patients allocated to aspirin used 30 mg as­
pirin daily (95%), whereas 3% used 75 mg and 2% 
had 100 mg aspirin daily. Patients allocated to antico­
agulant drugs visited the thrombosis centers with a 
mean interval of 2.6 (±1.8) weeks and somewhat more 
often during the first 6 months after randomization 
(mean interval, 1.9 [±1.2] weeks). During the trial 
143 patients who took anticoagulant drugs discontin-
trial medication; 44 did so in the group al-r
• I
(Table 2). patients
stopped using anticoagulants did so within 6 months 
after randomization. Figure 1 shows the number of
patient-years spent in each class of 0.5 INR unit dur­
ing the time that patients allocated to anticoagulants 
used their study drugs.
In the 60 patients with stroke, on follow-up, CT
mine the relationship between the intensity of ancico 
tion (in 0.5 INR units) and the incidence of major
werecomplications. Cox and Poisson nu
means of the EGRET statistical package [19|.
Results
Between April 23, 1993, and May 15, 1996, 1,316
patients were enrolled at 58 centers. (1,277)
patients originated from 52 Dutch centers whereas 
39 patients were randomized from other countries (see 
Appendix). The mean length of follow-up was 14
scanning was per in pane « ; in 2 pa-
tients the diagnosis was based on autopsy and in 5 on 
clinical history. In 4 of these 5 patients no certain dis­
tinction could be made between hemorrhage and in-
n focal brainfarction; 1 patient had a history of a s 
lesion rapidly evolving into herniation, which was clas­
sified as intracranial hemorrhage. Most CT scans were 
done within 2 weeks after onset of ;
and another 6% was done between 2 and 4 weeks.
Table 3 shows an f
event in the 651 patients on anticoagulant drugs; 81, 
months, with a range of 0 to 37 months. One random- against 36 in the 665 patients treated with aspirin. The
ization number was allocated to a person whose exis­
tence could, not be subsequently confirmed. Seven pa­
tients, of whom 2 were allocated to aspirin, were, in
lately enrolled in the trial; ie, 3
HR associated with the use of anticoagulants is 2.3
Cl, 1.6-3.5), the excess being attributable to ;
m inance of major ng complications in an-
patients. Figure 2
had a brain tumor, 1 amyotrophic lateral sclerosis, 1 
cervical myelopathy, and 2 atrial fibrillation; these 7
M e ie r
the Kaplan—
A)
m . ^  l.
and major bleeding complications (panel B) in both
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Table 1. Baseline Characteristics o f the Study Patients, line to Assie
Number allocated
Male (%)
Age >65 yr (%)
Qualifying event (%)
Transient monocular blindness 
Transient ischemic attack 
Minor ischemic stroke
Time from longest event to randomization (%) 
<1 wk 
1 wk to 1 mo 
1-6 mo
Rankin grade (%)
0
1
2
3
no symptoms
minor symptoms; no limitations
some restrictions; no help needed 
help needed; still independent
CT scan of the brain1 (n) 
Any infarct (%)
Any relevant infarct (%)
History (%)
Stroke
Angina pectoris 
Myocardial infarction 
Intermittent claudication
Diabetes mellitus
Vascular intervention 
Current cigarette smoking 
Hypertension
Blood pressure (mm Hg) 
Systolic 
Diastolic
1
Cholesterol (mmol/L) '
b
“ Not required in patients with transient monocular blindness.
h Mean ± SD.
CT computed tomographic.
On medication/at risk1 (% on medication) 
At start trial 
At 6 mo 
At 1 yr 
At 1.5 yr
At 2 yr
Reason for first discontinuation (n)
Inapprop riate i nclusi on
Nonfatal stroke or M I
Nonfatal major bleeding complication
Minor bleeding complication
Other adverse effect
Start other antithrombotic drugs
Other medical reason
Hassle anticoagulation conti-ol
Other reasons
Unknown
;l Patients alive at the start of the period.
1 Thirty-one patients never received anticoagulants and 3 patients never 
M I =  myocardial infarction.
Anticoagulants
651
66
47
5
36
58
14
34
52
45
27
19
10
624
49
39
9
9
9
5
11
7
46
39
158 24
91 ± 13 
6.1 ± 1.3
Table 2. When and Why Trial Medication Was Discontinued in the Study Patients
Anticoagulants
! m m )  [  ;■ I II ‘i 1 il I 1 < « M rru  n n - n  n i ^ i i . i  ‘i<«1|^ Wié'lt i  1 < 1^ 4 ttptA W''VI V 1
651/651 (100)
451/511 (88)
(81)
165/200 
94/112 (84)
I)
6
12
20
25
17
2
12
16
29
4
»DM»-«*.« >i H i I  »i.i.i'T«! ,^. w i-HMifl
aspirin as allocated.
—* » /M W H
Aspirin
665
63
48
3
37
60
14
33
53
43
29
21
8
646
46
35
8
12
10
7
13
6
44
46
158 ± 26
91 13
6.2 ± 1.3
. I .«  4 'fS+é* VIH T 4\W +'>. ' . ' • V r ' * ' ! .  V l..« *..
•  9
so inn
665/665 (100) 
483/510 (95)
345/373 (92)
197/215 (92)
114/125 (91)
1
1
2
?
1
3
21
1
0
2
1
-— ‘  . ^ . . . ! k  . . > > . i m  > . « i - i  .  K i ............ t .
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person-years
200
150
100
50
0
Q outs jdo  target 
E3Within target 
Q  Unknown INR
CD Early discontinuation
I  I
■ * I
W nMHi
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Fig 1. Distribution o f time spent in each international nor­
malized ratio class.
treatment groups. The H R  for death from all causes 
was 2.4 (95% Cl, 1.3-4.4). There was no statistically
significant difference in the occurrence of major is­
chemic events (nonhemorrhagic death from vascular 
causes, nonfatal ischemic stroke, or nonfatal myocardial 
infarction). The crude HRs shown in Table 3 re­
mained essentially the same after adjustment for major 
risk factors. We refrained from any of the planned sub­
group analyses because of the limited numbers of out­
come events.
Table 4 summarizes the types of major bleeding 
complications according to treatment group. Fourteen 
fatal brain hemorrhages occurred in the patients allo­
cated to anticoagulants, against only 1 in the aspirin 
group. In the anticoagulated patients, 27 intracranial 
bleeding complications occurred of which 23 were in­
tracerebral, 3 were subdural, and 1 was of unknown
A
tu
<a
cuÜ)
C
<D><D
B
time (days)
1.00
0.95
V-.
* S ,
aspirin
\
0,85 -
0.80-
0.75-
S .
m
»
«
»
«
anticoagulants
r
o 200 400 600 
time (days)
800 1000 1200
7 VI I 'J i /»Fig 2. (A) Kaplan—Meier curves for 
event o f "death from vascular causes, nonfatal stroke, nonfatal 
myocardial infarction, or non
»non, accordine to assume
•••'> > vc' corno uca-
rs o
tients at risk are shown in Table 2, (B) Kaplan—Meier curves 
for major bleeding complications according to assigned treat­
ment
Table 3. The Occurrence o f First Outcome Event? According to Allocated Treatment (Intention-to-Treat Analysis)
»I*.,!*-1— fi*« V*--- ['.urn —V-- I f.1'm » " '^ <1 I w - ^ 4 . / ,» |T,. »-1 • •» ■<, •.-.r-i'.-.W •— x A.J.VI -c .1. .i. .. I.- i 1---.. r k- -, . L .• t ■ ■ •■•«JV. ----•«*! "
b
Pati e n rs ran do mized 
Person-years of observation
Death from all vascular causes, nonfatal stroke, nonfatal MI, 
nonfatal major bleeding complication'-
C
Death from all vascular causes
Death from all vascular causes, nonfatal stroke
Major bleeding complication
All major ischemic events: nonhemorrhagic death from vascu­
lar causes, nonfatal ischemic stroke, MI
f i  MÌJ||>»>» l l ln n uM |:u «b M n ri I w *■■■■ ««»»ft n r*  •J'** V. v« *^-— .x .
AC ASA H R 95% Cl
fc. i-.*-. . -a yv-.'*. r. é-i.k'-,... r-Ji* t * >
651
735
- - S . <^*<•'11«*' '((' Ilfc'V'"* < .... . i
665
775
81 36 ") \A* # i/ 1.6-3.5
35 15 2.4 1.3-4.4
24 11 2.3 1.1—4.6
48 29 1.7 1.1 -2.7
53 6 9.3 4.0-22
27 27 1.03 0.6-1.75
Av AA-K4 li. ,*• JNri «Ml* -*A - -J J I *P •— t-J • »"i -«1 *. <.ì: *_W. *-J--r * - .*L‘ ‘ 4 fc'<* <^ L*L ft ’iü.æi ‘-------------- - .4 B ; V ' • ■ - • *i. '*• J* «*-■''«'« «
a One outcome event in the AC group and three in the ASA group were strokes that could be classified as neither ischemic noi 
because no computed tomographic scan was available,
h Person-years are given for the primary outcome event» The number of person-years for the other outcome events are slightly 
c Whichever event occurred first.
rrhagic
AC anticoagulants; ASA =  aspirin; H R  =  hazard ratio; C l =  confidence interval; M I —  myocardial infarction.
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Table 4. Bleeding Complications Ac coi'ding to
Treatment Group 100
Major Bleeding AC ASA
80Complication (n := 651) (n = 665)
Fatal intracerebral 14 1
A 60
Deepa 7 1
Lobar“ 5 0
Cerebellar1' 1 0 40
No CT scan1 1 0
Fatal subdural 1 0
20Fatal gastrointestinal 0 0
Fatal other0 2 0
Nonfatal intracerebral 10 2 n
Deep1 4 2
u
Lobar“ 3 0 A
Cerebellar1 3 0
Nonfatal subdural 2 0
100
Nonfatal gastrointestinal 10 2
Nonfatal urinary tract 7 0
Nonfatal other 7 1 80
Total 53 6
a Localization based on computed tomographic (CT) scanning or 
autopsy.
b Diagnosis based on clinical history: a 61-year-old man presenting 
with a right hemiparesis, aphasia, and progressive loss of conscious­
ness died within 6 hours after onset of symptoms. 
c One patient bled from an arteriovenous malformation in the liver 
hilus; another died from the sequelae of a massive bleed in a leg.
AC anticoagulants; ASA =  aspirin
location. Fifteen intracranial breedings were deep intra- 
cerebral or cerebellar hemorrhages. Age of more than
95% and
baseline
95% Cl, 3.4—16) were the most important risk factors 
for intracerebral hemorrhages. There were no statisti­
cally significant differences in the incidence of intrace­
rebral bleeding complications between patients with or 
without a history of hypertension, those with a lacunar 
or cortical infarction at their baseline CT scan, and 
those with a TIA versus a longer lasting qualifying 
event.
The incidence of major bleeding complications in­
creased steeply with the achieved intensity of anticoag-
ulation (Fig 3A). This is clearly in a
Poisson regression model; for each 0.5 INR unit the
incidence increased by a factor of 1.43 (95% Cl, 0.96-
2.13). Figure 3B suggests a decrease of the incidence of 
ischemic events with increasing intensities of anticoag­
ulation, although the CIs of the rate ratios are wide.
The decrease in a Poisson model is 0.83 (95% Cl,
0.65—1.07) for each 0.5 IN R  unit.
Discussion
This study was based on the premise that anticoagulant 
treatment would be more efficacious than aspirin in 
preventing recurrent episodes of cerebral ischemia, but
incidence/100 patient-years
■ : 1
11
V.Y*
liT ; 1 .
•y ,1 :. * >
V.\ ' ■ ■
,7
:<
: r
■. >1 : v ' -v./.'.i
■ \ 
i
1- 1,5- 2- 2,5- 3- 3,5- 4- 4,5- 5- 5,5- 6-
Incldence/lOO patient-years
60
40
20
0
1- 1,5- 2- 2,5- 3- 3,5- 4- 4,5- 5- 5,5- 6-
B
Fie 3. (A) International normalized ratio (INR)-specific inci- 
dence o f major bleeding complications with upper limits o f 
95% confidence interval. The line results from a Poisson re­
gression model. (B) INR-specific incidence o f ischemic compli­
cations with upper limits o f 95% confidence interval, 
results from a Poisson regression model.
the high rate of major bleeding complications led to 
the trial being terminated, at only 17% of its predeter­
mined number of patient-years of observation. At the 
time of the interim analysis, the hemorrhagic compli­
cations were numerous enough to lead to a statistically
significant erenee in the primary, composite out
come event of the trial (death from all vascular causes, 
nonfatal stroke, nonfatal myocardial infarction, or ma- 
j 0  r
Committee advised that this
x'ding complication). The Data Monitoring
illerence was suHicienr 
reason to discontinue the trial because the original hy­
pothesis assumed anticoagulants to be beneficial.
at a high target range of anticoagulation
4.5) for two reasons; ie, (1) in T
We ai
(IN R  vi
s as well as in other Eur an countries this
is the usual range for patients with arterial disease [5,
7, and (2) •nee available from s * L '
based on measurement of actual (rather than intended) 
INR values suggests the rate ol bleeding complications
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increases only when IN R  values rise above 4.5. Indica­
tions for anticoagulant use in these studies included 
myocardial infarction [20], artificial heart valves [21], 
and atrial fibrillation in combination with transient 
ischemic attacks or a nondisabling stroke [22]. Safety 
data from the European Atrial Fibrillation 
(EAFT) concerning patients with cerebral ischemia and 
atrial fibrillation appeared reassuring because the pa­
tients in that trial were relatively old (mean age, 71 
years) and none of the strokes documented with CT 
scanning (16 of 20) in the anticoagulant group were 
hemorrhagic. Moreover, the use of oral anticoagulant
drugs with a target IN R  range of 2.5 to 4.0 (and ob­
tained IN R  range of 2.0-3.5) was associated with a
risk for major v; ar events of 40% in
comparison with aspirin [11].
Intracerebral hemorrhage was the most frequent type 
of major bleeding complication (52%) in the anticoag­
ulated patients in this study. Why, then, were our pa­
tients so prone to intracerebral hemorrhage, when their 
TIAs or nondisabling strokes had not occurred in com­
bination with atrial fibrillation? It is likely that these 
patients had preexisting damage to the cerebral arterial 
tree, whereas of those with cerebral ischemia due to 
atrial fibrillation, the majority will have emboli origi­
nating from the left atrium. An alternate explanation is 
that these events represented hemorrhagic transforma­
tion, but the preponderance of deep intracerebral or 
cerebellar hemorrhages (see Table 4) would be contrary 
to this in that large hemorrhagic infarcts would be ex­
pected to occur mainly in superficial areas, correspond­
ing to the territory of major arteries or their branches. 
A third explanation would be that some 
events may, in fact, have been caused by small hemor­
rhages due to amyloid angiopathy [23], thus predispos­
ing patients to large hemorrhages during anticoagulant 
treatment, as may occur after thrombolytic treatment 
for myocardial infarction. Again, if this were
ance of lobar intracerebral hemorrhages 
•ather than the predominantly deep sites of bleeding
would be expected [24, 25]. Moreover, there was no
excess risk of intracerebral hemorrhage in patients with 
TIAs compared with those with nondisabling ischemic 
strokes (in whom CT generally ruled out hemorrhages 
and showed positive evidence of infarction).
If neither hemorrhagic transformation nor previous 
small hemorrhages are causing the frequent occurrence 
of intracerebral hemorrhage in the anticoag
case, a
i
treated patients, is there preexisting damage to the wall 
of small perforating brain arteries? If this were the case, 
the risk of intracerebral bleeding would be especially 
high in patients whose clinical or radiological features 
at presentation suggested involvement of small vessels 
26], i.e., lacunar or subcortical infarcts or, in the ab­
sence of evidence of infarction on CT scanning, “lacu-
nar transient ischemic attacks.” We not demon-
strate, however, a difference in the risk of intracerebral 
hemorrhage between patients with a lacunar or cortical 
infarction at their baseline CT scan. The only marker 
of small-vessel disease associated with the risk of intra­
cerebral hemorrhage was the presence of diffuse ische­
mic damage to the white matter of the brain (as as­
sessed on CT scans), and, to a much lesser extent, the 
patient’s age and the presence of arterial hypertension.
The results of this trial can probably be generalized 
to all patients with TIAs or nondisabling ischemic 
strokes except those in atrial fibrillation or those with 
tight carotid stenosis requiring surgery, given that the 
two patient groups were well balanced for all major 
prognostic variables, and that the patients in the aspi-
nn group were str ar to ?e in a previous
trial, in which we compared two different doses of as­
pirin [4]. The open design of our study might be re­
garded, by some, as a drawback, leading to information 
bias and thus detracting from the validity of our re­
sults; but as the assessment of outcome events was 
completely masked, we think this disadvantage has 
been overcome. What is more, there are advantages of 
an open trial with anticoagulant drugs. These lie not 
only in the simplicity of its organization, but also in 
that the comparison is truly that of strategies (one 
complex, the other simple) and not only of drugs (both 
with a complex mode of administration because of the 
use of double dummies), so that the results are fully 
analogous to clinical reality [27].
We do not expect that these results will end the de­
bate about the use of anticoagulant treatment in the
stroke for patients in sinus 
rhythm. The hypothesis for this trial was that the rate
;mic events in patients TIAs or
abling strokes might be substantially lower with anti­
coagulant treatment than with aspirin, which drug 
prevents only 15 to 20% of all major vascular compli­
cations [21. The numbers of outcome events of isch-
emic stroke, myocai infarction nonhemor-
rhagic death from vascular causes were so low at the
time the trial was stopped for safety reasons that the 
results are both compatible with a relative risk reduc­
tion of ischemic events by oral anticoagulants 
40% and with a relative risk reduction of ischemic 
events by aspirin with 43%; this is also reflected by the 
wide interval of the confidence interval of the slope of
line for the ischemic events. An 
ongoing trial in the United States [28] is comparing 
aspirin with anticoagulation with an INR target range 
of 1.4 to 2.8, and one would hope that this intensity is 
not only safe but also efficacious. In an observational
atrial riskstudy of patients 
stroke rose steeply at INR values measured to be lower 
than 2.0 [29], whereas in a randomized trial anticoag­
ulation with an INR target range of 2.0 to 3.0 could
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safely prevent ischemic stroke in high-risk patients with denberg (22; H. R. F. Bottger, M. F. Driessen-Kletter and F.
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atrial fibrillation [30],
Calculation of INR-specific incidence rates [16, 20- 
22] has allowed us to estimate that shifting the target 
range of anticoagulation to an IN R  range of 2.0 to 3.0 
(instead of 3.0-4.5) would reduce the rate of major
two iesults in
Figure 1 indicate that the thrombosis centers were 
fairly successful in keeping patients within the target 
range of IN R  values; a considerable number of the out­
lying values were from the initial dosing titration. Ex­
cluding patients more than 75 years old and those with 
leukoaraiosis might also improve safety, although the 
intensity of anticoagulation is a much more powerful 
risk factor than aee [31, 321. Whether the remaining:
Zwols); St Lucas Ziekenhuis Winschoten (22; J. B. van der 
Gaast and M. C. Wittebol); Academisch Ziekenhuis Maas­
tricht (21; J. Lodder and R. J. van Oostenbrugge); Zieken­
huis Nij Smellinghe Drachten (19; K. D. Beintema, J. Hil- 
bers and H. L. van der Wiel); St Anna Ziekenhuis Geldrop 
(18; H. B. M. van Lieshout); Diakonessenhuis Utrecht (17; 
W. Weststrate); Ziekenhuis St Jansdal Harderwijk (16; 
P. L. J. A. Bernsen); Canisius Wilhelmina Ziekenhuis 
Nijmegen (15; C. W. G. M. Frenken,*'|' and E. F. J. Poels); 
Twenteborg Ziekenhuis Almelo (14; S. F. Lindeboom); 
Streekziekenhuis Zevenaar (13; A. van der Steen); IJsselmeer 
Ziekenhuizen Emmeloord (12; W . F. Glimmerveen, E. I. F.
Martens); St Franciscus uis .terdam (12; C. Bu-
lens,1,1 L. H, Penning de Vries-Bos); Royal Flallamshire Hos­
pital Sheffield, UK (12; G. S. Venables*); Medisch Centrum
disadvantage would be outweighed by an even greater Leeuwarden (11; J. G. Koster and L. G. F. Sinnige); Streek- 
benefit in the prevention of ischemic events, compared ziekenhuis Midden Twente Hengelo (10; M. M. Klaver and
rrnm *■ h i 4 4 .W'W. V j  m *  é • ■ V  a *
with optimal antiplatelet treatment, is a question that J- C. Koetsveld-Baart); St Antonius Ziekenhuis Nieuwegein
J L  A  y  . ,:J_ V V  te  W  w  w  ^  ^  ^  f  ' S  I  % if 4  Mr-* m
can be settled only by a new trial of sufficient size. 
This trial, the European and Australian Stroke Preven-
tion In Reversible Ischemia 
recently.
(ESPRIT), started
(10; H. W. Mauser); Kennemer Gasthuis-lokatie 
IJmuiden (10; J. A. Don); Beatrix Ziekenhuis Gorinchem (9; 
R. B. Alting van Geusau, M. H. Dijkman and W. J. J. F. 
Hoppenbrouwers); St Jam es's University Hospital Leeds, UK 
(9; J. M. Bamford); Diaconessenhuis Leiden (9; P. E. Briët
Appendix
The following centers and investigators participated in the 
Stroke Prevention in Reversible Ischemia Trial. The number 
of patients randomized at each center is given in parentheses.
and J. L. A. Eekhof); Academisch Ziekenhuis V. U. Amster­
dam (7; R. Witjes); Slotervaart Ziekenhuis Amsterdam (6; 
H. L. Hamburger and J. J. van der Sande); King’s College 
Hospital London, UK (6; P. Bath); Royal Perth Hospital 
Perth, Australia (6; G. J. Hankey); N. H. Diaconessen Inrich-
Ziekenhuis De Wever and Gregorius Heerlen (126; C. L.
Franke,*t and P. J. J. Koehler); Ziekenhuis
Utrecht (111; J. W. Gorter,* L. J. Kappelle,*t G. J. E. 
Rinkel, H. C. Tjeerdsma,* and J. van Gijn,*f); Medisch 
Centrum Alkmaar (88; J. W. H. H. Dammers, H. J. S. 
Straatman, R. ten Houten, and M. M. Veering); Academisch
ijkzigt (79; S. L. M. Bakker, 
Dippel, P. J. Koudstaal,*1‘ H. M. A. van Gemert, and J. C.
Medisch Centrum Amsterdam 
(76; J. Horn, I. H. Kwa, M. Limburg, and J. Stam); Oost- 
erschelde Ziekenhuis Goes (60; A. M. Boon, W. H. G. Lieu- 
wens, and F. Visseher); Martini Ziekenhuis Groningen (58; 
C. Bouwsma, A. W. F. Rutgers, and J. W. Snoek); Medisch
van
Spectrum Twente Enschede ; P. J. A. M. Brouwers, J.
Nihom, and H. Solleveld); Merwede-ziekenhuis Dordrecht 
(38; P. A. T. Carbaat, L. I. Hertzberger, R. P. Kleijweg, anti 
V. M. H. Nanninga-van den Nes te); St Jozeiziekenhuis 
Kerkrade (38; A. J. H. van Diepen); St Lucas Andreas Ziek­
enhuis Amsterdam (37; W. H. ]. P. Linssen, J. A. L. Van- 
neste, J. Vos, and H. C. Weinstein); Ziekenhuis Bethesda 
Hoogeveen (32; J. P. Schipper and W. K. van der Meer); De 
Lievensberg Bergen op Zoom (30; P. J. 1. M. Berntsen); 
Zuiderzee Ziekenhuis Lelystad (30; E. M. de Vries-Lcenders, 
J. P. Geervliet, and R. J. J. Tans); St. Deventer Ziekenhuizen 
Deventer (28; W. J. Feikema and H. J. M. M. Lohmann); 
Westeinde Ziekenhuis’s-Gravenhage (26; V. van Kasteel); 
Ziekenhuis Rijnstate Arnhem (24; F. A. Jongebloed, Q. H. 
Leyten and P. J. M. van Wensen); Ziekenhuis De Gelderse 
Vallei Ede (24; C. Jansen and M. G. Smits); Holy Zieken­
huis Vlaardingen (24; J. J. M. Driesen, W. F. van Oudenaar­
den and J. C. B. Verhey); Streekziekenhuis Coevorden/Har-
ting Meppel (5; E. Koning); Clinico Neurologica-Policlinic 
Perugia, Italy (5; S. Ricci); Catharina Ziekenhuis Eindhoven 
(4; J. N. Berendes); St Franciscus Ziekenhuis Roosendaal (4; 
L. J. M. A. Flo off, A. C. Ci. A. van Spreeken, and H. N. A.
l'levo Ziekenhuis Almere (3; A. R. and
G. N. Mallo); Onze Lieve Vrouwe Gasthuis Amsterdam (3;
1.1. K. van Walbeek); Waterland Ziekenhuis Purmerend (3;
J. C. Gauw); Diaconessenhuis Eindhoven (2; A. J. Vermeij); 
Schieland Ziekenhuis Schiedam (2; J. C  B. Verheij); Reinier 
de Graaf Gasthuis Delft (1; J. W. A. Swen); Hospital de Santa 
Maria Lisbon, Portugal (1; P. Canhao); Academisch Zieken­
huis Nijmegen (1; A. Keyser); Antonius Ziekenhuis Sneek (l; 
R. S. Holscher); Diaconessenhuis Voorburg (1; Ci. J. tie Jong); 
and Lorentz Ziekenhuis Zeist (I; V. Kraaier).
Other contributors: A. Algra,* University Hospital Utrecht; 
E. Briët,t Academic Medical ('enter Amsterdam; ). de Vries- 
GoltLschmeding/ The Federation of Dutch Thrombosis ('en­
ters, Den Haag; B. C. Eikelboom,§ University Ilospital 
Utrecht; P. ( ireebe' R. N. W. Hauer 
University Hospital Utrecht; E. A. Loeliger,§ Oegstgeest; 
G. A. M. Pop,f Holy Hospital Vlaardingen; F. R. Rosendaal,§ 
University Flospital Leiden; A. F. A. M. Schobben,* Univer­
sity Flospital Utrecht; M. L„ Simoons,§ Thoraxcentrum, Eras­
mus Universkeit Rotterdam; J. ï. Sixma^ and I). C. V.
m-t *
Slabbers, University Hospital Utrecht; J. G. P. Tijssen,§ Ac­
ademic Medical Center Amsterdam; H. van Crevel,:|: Amster­
dam; G. A. van Es,:|: Rotterdam; F. W. A. Verheugt,t Uni-
M. Vermeulen,'1' Academicvers Hospital 
al Center sterdam; E. F. I), Weverf and E. K. M
Wulfsen, University Hospital Utrecht.
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